Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Withdraws Pediatric Data-Submission Rule, But Aims To Regroup Shortly

This article was originally published in The Gray Sheet

Executive Summary

FDA has 1withdrawn a new regulation that would have required companies to submit additional pediatric patient data as part of pre-market submissions beginning next month, but says it hopes to finalize a possibly revised version soon

You may also be interested in...



Guidance Finalized On Submitting Pediatric Info To FDA In Device Submissions

The agency issued its final guidance April 30 on reporting “readily available” information on pediatric subpopulations in device submissions. As with the 2013 draft version, it backs off on a pre-draft proposed rule that would have asked firms to provide data on potential, or possible, pediatric uses of devices.

Industry Largely Supports FDA’s New Proposal On Pediatric Data Submission

Device companies are generally happy with FDA’s rewrite of a rule requiring information on pediatric populations suffering from conditions their devices are intended to treat. The American Academy of Pediatrics is less pleased.

FDA Proposal Requires Firms To Submit Public Data On Pediatric Populations

The Feb. 19 proposed rule implements requirements from the Pediatric Medical Device Safety and Improvement Act – passed as part of the 2007 FDA Amendments Act. The rulemaking was held up by concerns expressed by industry, which appear to have been addressed by the agency.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel